Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease…
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in…
Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy…
AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center…
July 11, 2025 16:30 ET | Source: Ultragenyx Pharmaceutical Inc. Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls…
Two pioneering scientists received The Brain Prize 2025 for their discoveries that open an entirely new way of thinking about…